No Data
Shanxi C&Y Pharmaceutical Group (300254.SZ): plans to extend the "new drug research and development project of the pharmaceutical Rosabastat and capsules" to December 2026.
Gelonghui, December 24 - Shanxi C&Y Pharmaceutical Group (300254.SZ) announced that on December 24, 2024, it will hold the twenty-fourth meeting of the fifth Board of Directors and the eighteenth meeting of the fifth Board of Supervisors to review and approve the proposal regarding the extension of certain fundraising projects. It is agreed that under the premise that there are no changes in the implementation entity, implementation method, use of raised funds, and investment scale of the fundraising project for issuing stocks to specific objects in 2020, the time for the "new drug research and development project for pharmaceutical Rosuvastatin and capsules" to reach the predetermined usable state will be extended to December 2026.
Shanxi C&Y Pharmaceutical Group (300254.SZ): Subsidiary maltol iron capsules approved to conduct clinical trials.
Guangdong Hongkong Commercial Daily reported on December 24 that Shanxi C&Y Pharmaceutical Group (300254.SZ) recently announced that its subsidiary, Hangzhou Qianyuan Baoling Pharmaceutical Co., Ltd., received the "Approval Notice for Clinical Trials" from the National Medical Products Administration for "Maltol Iron Capsules". The company will begin clinical trials shortly. Maltol Iron Capsules are suitable for the treatment of iron deficiency anemia in adults. Maltol iron is a complex containing iron ions, which differs from iron salt compounds; it dissociates when absorbed by the gastrointestinal tract, with iron ions and maltol being absorbed separately. Iron ions are taken up by intestinal wall cells and transferred to the bloodstream.
Shanxi c&y pharmaceutical group (300254.SZ) subsidiary has received the pharmaceutical registration certificate and the approval notice for the application to market chemical raw materials.
Shanxi C&Y Pharmaceutical Group (300254.SZ) announced that recently, its subsidiary Hangzhou Qianyuan Baoling Pharmaceutical Co., Ltd. received...
Shanxi c&y pharmaceutical group (300254.SZ) plans to establish a wholly-owned subsidiary to accelerate the research and development of new products in categories such as refined and controlled drugs.
Shanxi c&y pharmaceutical group (300254.SZ) announced that on November 25, 2024, the company's fifth board of directors will hold its twenty...
shanxi c&y pharmaceutical group (300254.SZ): Subsidiary receives corporate support funds of 5 million yuan
Gelonghui, November 19th: Shanxi C&Y Pharmaceutical Group (300254.SZ) announced that its subsidiary, Tibet Shanxi C&Y Pharmaceutical Co., Ltd. (hereinafter referred to as "Tibet Shanxi C&Y"), received enterprise support funds of 5 million yuan from the Management Committee of Tibet Autonomous Region Tsangqing Industrial Park on November 19, 2024, accounting for 19.84% of the company's most recent audited net income.
shanxi c&y pharmaceutical group (300254.SZ): Currently, the company's products have not yet involved biotechnology.
Gelonghui November 11th | shanxi c&y pharmaceutical group (300254.SZ) stated on the investor interaction platform that currently the company's products are not yet involved in biotechnology synthesis technology.
ShanXi C&Y Pharmaceutical Group Co., Ltd. (SZSE:300254) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough
